A number of other brokerages have also recently commented on CELG. BMO Capital Markets lifted their price target on Celgene from $148.00 to $155.00 and gave the stock an outperform rating in a research report on Friday, November 17th. Oppenheimer reissued a buy rating and issued a $170.00 price objective on shares of Celgene in a report on Friday, October 20th. Vetr raised Celgene from a buy rating to a strong-buy rating and set a $144.39 price objective for the company in a report on Monday, October 23rd. Cann reissued a buy rating on shares of Celgene in a report on Thursday, October 26th. Finally, Morgan Stanley raised Celgene from an underweight rating to an equal weight rating in a report on Friday, October 27th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company’s stock. Celgene has a consensus rating of Buy and an average price target of $130.35.
Shares of Celgene (CELG) traded up $1.49 on Wednesday, reaching $92.51. The company’s stock had a trading volume of 10,465,217 shares, compared to its average volume of 8,240,000. Celgene has a 12 month low of $88.32 and a 12 month high of $147.17. The company has a current ratio of 4.99, a quick ratio of 3.52 and a debt-to-equity ratio of 2.29. The firm has a market cap of $69,580.00, a PE ratio of 25.63, a P/E/G ratio of 0.66 and a beta of 1.49.
Celgene (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 EPS for the quarter, topping the Zacks’ consensus estimate of $1.78 by $0.09. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The company had revenue of $3.48 billion during the quarter, compared to analysts’ expectations of $3.46 billion. During the same quarter in the previous year, the firm posted $1.61 EPS. The firm’s revenue was up 16.9% compared to the same quarter last year. equities research analysts predict that Celgene will post 7.68 EPS for the current fiscal year.
In other Celgene news, insider Mark J. Alles acquired 3,260 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The shares were purchased at an average cost of $91.90 per share, for a total transaction of $299,594.00. Following the completion of the acquisition, the insider now owns 178,904 shares of the company’s stock, valued at approximately $16,441,277.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.95% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CELG. Grisanti Capital Management LLC acquired a new position in Celgene during the second quarter worth $3,616,000. RiverPoint Capital Management LLC lifted its stake in Celgene by 3.1% during the second quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock worth $15,799,000 after purchasing an additional 3,680 shares in the last quarter. LSV Asset Management acquired a new position in Celgene during the second quarter worth $1,701,000. Spectrum Management Group Inc. acquired a new position in Celgene during the second quarter worth $462,000. Finally, Polen Capital Management LLC lifted its stake in Celgene by 7.7% during the second quarter. Polen Capital Management LLC now owns 5,082,991 shares of the biopharmaceutical company’s stock worth $660,128,000 after purchasing an additional 363,108 shares in the last quarter. Hedge funds and other institutional investors own 78.93% of the company’s stock.
WARNING: “Celgene (CELG) Given a $128.00 Price Target at Mizuho” was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://ledgergazette.com/2018/02/12/mizuho-reaffirms-buy-rating-for-celgene-celg.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.